Skip to main content
Back
LLY logo

Eli Lilly and Company

Data quality: 100%
LLY
NYSE Healthcare Drug Manufacturers - General
$910.55
▲ $3.85 (0.42%)
Mkt Cap: 860.30B
Day Range
$907.23 $926.78
52-Week Range
$623.78 $1,133.95
Volume
2,127,912
50D / 200D Avg
$1,024.73 / $892.56
Prev Close
$906.70

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 41.7 0.4
P/B 32.4 2.9
ROE % 101.4 3.8
Net Margin % 31.7 3.9
Rev Growth 5Y % 23.2 10.0
D/E 1.6 0.2

Analyst Price Target

Hold
$1,243.95 +36.6%
Low: $985.00 High: $1,350.00
Forward P/E
26.5
Forward EPS
$34.43
EPS Growth (est.)
+0.0%
Est. Revenue
82 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $60.97
$56.29 – $66.45
 130 B 3
FY2029 $55.40
$51.14 – $60.38
 120 B 3
FY2028 $49.21
$42.81 – $55.86
 110 B 9

Key Takeaways

Revenue grew 23.17% annually over 5 years — strong growth
Earnings grew 94.88% over the past year
ROE of 101.35% indicates high profitability
Net margin of 31.66% shows strong profitability
Generating 8.97B in free cash flow
P/E of 41.68 — premium valuation

Growth

Revenue Growth (5Y)
23.17%
Revenue (1Y)44.70%
Earnings (1Y)94.88%
FCF Growth (3Y)N/A

Quality

Return on Equity
101.35%
ROIC32.26%
Net Margin31.66%
Op. Margin45.56%

Safety

Debt / Equity
1.60
Current Ratio1.58
Interest Coverage37.34

Valuation

P/E Ratio
41.68
P/B Ratio32.42
EV/EBITDA30.16
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 44.70% Revenue Growth (3Y) 38.20%
Earnings Growth (1Y) 94.88% Earnings Growth (3Y) 98.45%
Revenue Growth (5Y) 23.17% Earnings Growth (5Y) 38.67%
Profitability
Revenue (TTM) 65.18B Net Income (TTM) 20.64B
ROE 101.35% ROA 18.35%
Gross Margin 83.79% Operating Margin 45.56%
Net Margin 31.66% Free Cash Flow (TTM) 8.97B
ROIC 32.26% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.60 Current Ratio 1.58
Interest Coverage 37.34 Dividend Yield 0.01%
Valuation
P/E Ratio 41.68 P/B Ratio 32.42
P/S Ratio 13.20 PEG Ratio 0.49
EV/EBITDA 30.16 Dividend Yield 0.01%
Market Cap 860.30B Enterprise Value 895.64B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 65.18B 45.04B 34.12B 28.54B 28.32B
Net Income 20.64B 10.59B 5.24B 6.24B 5.58B
EPS (Diluted) 22.95 11.71 5.80 6.57 5.85
Gross Profit 54.62B 36.62B 27.04B 21.91B 21.01B
Operating Income 29.70B 17.50B 10.79B 8.65B 7.93B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 112.48B 78.71B 64.01B 49.49B 48.81B
Total Liabilities 85.94B 64.44B 53.14B 38.71B 39.65B
Shareholders' Equity 26.54B 14.19B 10.77B 10.65B 8.98B
Total Debt 42.50B 33.64B 25.23B 16.24B 16.88B
Cash & Equivalents 7.16B 3.27B 2.82B 2.07B 3.82B
Current Assets 55.63B 32.74B 25.73B 18.03B 18.45B
Current Liabilities 35.23B 28.38B 27.29B 17.14B 15.05B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Growth Investing (Philip Fisher)
#13 of 154
89
Custom Full Throttle
#43 of 146
54

Recent Activity

Entered Growth Investing (Philip Fisher)
Mar 24, 2026
Entered Full Throttle
Mar 24, 2026